A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Completed · Phase 2

Conditions studied: Presbyopia

In brief

This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

Key facts

Study ID
NCT02595528
Run by
Allergan
People needed
163
Starts
2016-04-29
Expected to finish
2017-10-18
Last updated by the study team
2020-12-22

Who can join

Age: 40 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.